Research graph
References from Clinical Impact and Dynamics of Clonal Hematopoiesis with 177 Lu-PSMA-617 Therapy in Advanced Prostate Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
10.1016/j.annonc.2025.07.003 · 2025 · External reference
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
10.2967/jnumed.124.268640
10.2967/jnumed.124.268640 · External reference
10.1182/blood.2023022222
10.1182/blood.2023022222 · External reference
10.1158/0008-5472.can-22-0985
10.1158/0008-5472.can-22-0985 · External reference
10.1038/s41588-020-00710-0
10.1038/s41588-020-00710-0 · External reference
10.1038/s41467-018-02858-0
10.1038/s41467-018-02858-0 · External reference
10.1002/pros.24712
10.1002/pros.24712 · External reference
10.1158/1078-0432.c.8568802
10.1158/1078-0432.c.8568802 · External reference
10.1016/j.jmoldx.2024.03.007
10.1016/j.jmoldx.2024.03.007 · External reference
Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade
2020 · External reference
10.1200/jco.2016.71.6712
10.1200/jco.2016.71.6712 · External reference
Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)
10.1158/1078-0432.ccr-24-0803 · 2024 · External reference
10.1016/j.stem.2017.07.010
10.1016/j.stem.2017.07.010 · External reference
Clonal hematopoiesis in prostate cancer inferred from somatic tumor profiling
10.1200/jco.2021.39.15_suppl.e17001 · 2021 · External reference
Clonal hematopoiesis landscape in metastatic prostate cancer patients
10.1182/blood-2024-206483 · 2024 · External reference
Clinical consequences of therapy related clonal hematopoiesis in patients treated with PSMA-targeted radionuclide therapy
10.1016/j.annonc.2025.08.3034 · 2025 · External reference
Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy
10.1200/po.21.00309 · 2022 · External reference
Prediction of risk for myeloid malignancy in clonal hematopoiesis
10.1056/evidoa2200310 · 2023 · External reference
10.1038/s41591-018-0081-z
10.1038/s41591-018-0081-z · External reference
10.1038/s41586-018-0317-6
10.1038/s41586-018-0317-6 · External reference
PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC) [abstract]
10.1200/jco.2025.43.16_suppl.tps5127 · 2025 · External reference
10.1016/j.annonc.2025.09.101
10.1016/j.annonc.2025.09.101 · External reference
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design
10.1016/s0140-6736(24)01865-8 · 2024 · External reference
10.1001/jama.294.4.433
10.1001/jama.294.4.433 · External reference
